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adverse events). In a multivariate analysis the variables associ-
ated with satisfaction were: ß2 agonist (p = 0.071) and males 
(p = 0.051). CONCLUSIONS: Patient satisfaction with COPD
treatment is high and is related with the low frequency of adverse
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OBJECTIVES: To estimate the cost of red blood cell (RBC)
transfusion using three different techniques, i.e. allogeneic trans-
fusion, autologous transfusion and perioperative auto-transfu-
sion, from a societal perspective for Sweden. METHODS: Data
concerning the sequence of procedures involved in the collection,
preparation and transfusion of RBCs and perioperative auto-
transfusion was collected from the Swedish National Board of
Health and Welfare, from other published sources and from
interviews with staff at ﬁve large Swedish hospitals. Direct hos-
pital costs were derived from the Southern Regional Health Care
Board and from Haemonetics Scandinavia AB. Income data on
hospital staff was derived from the Swedish federation of county
councils. Data for estimating indirect costs have been obtained
from Statistics Sweden and the National Tax Board of Sweden.
RESULTS: The cost of a 2-unit transfusion was found to be
SEK7 144 (€792) for ﬁltered allogeneic RBCs and SEK5
394(€598) for autologous RBCs for surgery patients. Transfu-
sion reactions accounted for more than 40 percent of the costs
of allogeneic RBC transfusions. The administration cost was
found to be much higher for autologous transfusions compared
to allogeneic transfusions. The cost of intraoperative erythrocyte
salvage was calculated to be SEK2567 (€285) per transfusion (>4
units). Of the three available techniques, allogeneic RBC trans-
fusion is the most common method used in Sweden. More than
99% of all donated blood is allogeneic in the case of Sweden.
CONCLUSIONS: Patients who suffer from anaemia have the
option of treatment with blood transfusion or treatment with
erythropoietic stimulating agents. From a societal perspective,
allogeneic RBC transfusions are considerably more costly than
the perceived cost at the hospitals. Allogeneic transfusion were
found to be more costly than autologous transfusions concern-
ing transfusion reactions but less costly with respect to adminis-
tration at the blood centres.
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OBJECTIVES: To estimate the cost-effectiveness of remifen-
tanil/propofol versus fentanyl/propofol as regimen of total intra-
venous anesthesia using infusion pump in Mexican Health
Sector. METHODS: An expert panel with anesthesiologists was
established to identify the medical and non-medical health
resources used to perform a general anesthesia in patients with
65kg, ASA I (American Society of Anesthesiologists) for a range
in the anesthetic time from 60 to 180 minutes and the effective-
ness accomplished with the regimens. The information gathered
from the expert panel was completed with a literature review.
Ofﬁcial unitary costs for the Mexican Institute of Social Security
(IMSS) and Hospitals from The Ministry of Health were used.
The expected cost per patient included the costs of drugs, post-
anesthetic care unit, labor costs and costs associated with adverse
events. Costs were expressed in Mexican Pesos and then con-
verted to US dollars (rate exchange 11 Mexican pesos = 1USD).
RESULTS: For the remifentanil/propofol regimen the induction
doses were 1mcg/kg remifentanil and 2mg/kg propofol; the
maintenance doses were 0.5mcg/kg/min remifentanil and 85
mcg/kg/min. For the fentanyl/propofol group the induction doses
were 3mcg/kg fentanyl and 2mg/kg propofol; the maintenance
doses were 3mcg/kg/hour fentanyl and 120mcg/kg/min. For the
median of anesthetic time, 120 minutes, the costs per anesthesia
were $1421 (129 USD) and $1644 (149 USD) for the remifen-
tanil/propofol and fentanyl/propofol regimen, respectively. The
average extubation time was 7 minutes for the regimen with
remifentanil, and 15 minutes with fentanyl. Using a visual ana-
logue scale, where 0 represents the worst value and 10 the best,
the remifentanil/propofol regimen was graded 9.6 and the fen-
tanyl/propofol 8.6. CONCLUSIONS: Regimens with remifen-
tanil/propofol dominates fentanyl/propofol techniques, since
they provide a highly effective and secure anesthesia and also
represents a signiﬁcant saving in total resources used (mainly in
use of propofol and post-anesthetic care unit) offsetting its higher
acquisition costs.
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OBJECTIVE: To evaluate cost of antibiotic therapy in patients
undergoing colorectal surgery and possible inﬂuence of post-
surgical infections on hospital costs. METHODS: We conducted
a naturalistic, retrospective study, collecting data from medical
records on patients undergoing surgery in 2002–2004, from two
Italian hospitals. Analyses were conducted from the hospital’s
point of view: cost of treatment (expressed as €/hospitalization,
values of 2005) and length of post-surgical stay as a proxy of
hospital cost are reported, with comparisons among the two hos-
pitals (HOSP1 and HOSP2). The bootstrap resampling method
(5000 samples) was applied to have more reliable results.
RESULTS: Data of 174 patients (mean age 68.3, 38–93 years,
49.4% men) was collected: 82.8% underwent surgery for malig-
nant cancer, 2.3% for benign cancer, 14.9% for other reasons.
Antibiotic therapy was applied by adopting two different guide-
lines: in HOSP1 patients were treated with 5-nitroimidazole 
and ceftazidime or cefotassime. If infections occurred,
cephalosporins, ﬂuoroquinolones, quinolones, carbapenems,
penicillines were used, according to the type of infections.
Patients from HOSP2 were preventively treated with: cefotetan
or cefoxitine, or 5-nitroimidazole + gentamicine or piperacilline
+ 5-nitroimidazole. The infected patients were treated with car-
bapenems, penicillines, cephalosporins, triazoles, amynoglico-
sides, and ﬂuoroquinolones. Thirty-eight patients (22%) were
infected, with similar frequencies in the two hospitals. Therapy
cost on average €140.59 (€0.0–816.13), with signiﬁcant differ-
ence between non infected and infected patients (97.24 vs.
€293.99, p < 0.0001). The average cost was higher in HOSP1
(€182.45 vs. €102.40, p < 0.001) while the median post-surgical
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hospital stay was higher in HOSP2 (11.3 vs. 14.5, p < 0.01). Sig-
niﬁcant differences were anyway conﬁrmed only among non
infected patients. Our results were not conﬁrmed with the boot-
strap method. CONCLUSIONS: Cost of antibiotic therapy, its
effects on the risk of infections and length of remission can be
inﬂuenced by the therapeutic choices. Information on potential
consequences is useful to implement optimal therapeutic
approaches.
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OBJECTIVES: The aim of this study to calculate the health
insurance cost of treatment of patients with peritrochanter frac-
ture of femur from the ﬁrst hospital admission for 18 months
follow up period according to most frequently used 4 different
surgical methods (ender nailing, ﬁx angled plate, gamma nailing
and dynamic hip screw ﬁxation (DHS). METHODS: Recruit-
ment criteria were: 1) all patients with a hip fracture in 2000
deﬁned by the International Classiﬁcation of Disease (ICD) as
“S7210”; 2)working age between 18–65; 3) ﬁrst admission to
surgical unit, and had an operation because of monotraumatic
peritrochanteric fracture of femur; and 4) without comorbidities.
The cost analysis includes the cost of acute and chronic in-patient
care, outpatient care and sick pay. RESULTS: The total number
of patients having peritrochanteric fracture of the femur was
1154. Due to the inclusion criteria listed in the data and methods
chapter altogether 186 patients were included into the study. The
total costs were the highest in case of those types of operations
with lower cost of prosthesis device and lower load stability:
Ender nailing €2322, ﬁx angled plate €2109 because of the
higher sick-pay costs. The total costs were the lowest in case of
those types of operations with higher cost of prosthesis device
and higher load stability (Gamma nailing €2022, dynamic hip
screw €1836) because of the lower sick-pay costs. The average
days spent on sickness-pay varied according to the types of sur-
gical methods. Gamma nailing-182 days, DHS ﬁxation-212
days, Ender nailing—310 days, ﬁx angled plate—269 days.
CONCLUSION: In case of surgical methods with lower com-
plication rate and quicker load stability (Gamma nailing, DHS
ﬁxation) the cost of primary treatment is higher but the total
costs are lower because of lower additional costs (chronic care,
sickness-pay).
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OBJECTIVE: The purpose of this study was to analyze blood
transfusion patterns and associated costs by various spinal
surgery subtypes in the US inpatient setting. METHODS: This
study used Premier’s US Inpatient Comparative Database, con-
taining approximately 5 million admissions annually, from over
500 hospitals. A total of 31,808 inpatient discharges with
primary procedure codes for spinal fusion surgery (ICD-9 codes
81.01–81.08, 81.31–81.38, 81.61; US projected total: 274,523)
between July 2003 and June 2004 were selected and stratiﬁed
into seven surgical subtypes based on the anatomic location of
fused vertebrae and surgical technique. Blood management pat-
terns were examined pre- and post-surgery. The association
between spinal surgery subtypes and blood transfusion costs
were examined using multivariate regression after controlling for
various patient-(age, race, gender, severity), hospital-(location,
teaching status, bedsize, region), and clinical-factors, inpatient
mortality, payer type (Medicare, Medicaid, commercial/managed
care), and physician specialty. RESULTS: Spinal fusion surgeries
incurred average (maximum) blood transfusion costs of
$149–$493 ($3,300–$13,120) per surgery, depending on
subtype. As compared to cervical fusions, dorsal/dorsolumbar
and lumbar/lumbosacral fusions as well as refusions were 
associated with signiﬁcantly higher blood transfusion costs
($100–$195; p < 0.0001). Being operated by a neurosurgeon was
associated with lower blood transfusion costs (p < 0.0001).
Blood transfusion costs increased with increasing patient sever-
ity ($967), hospital bedsize ($100–$142), and urban/teaching
status (p < 0.0001). Use of volume expanders and erythropoetic
agents signiﬁcantly increased blood transfusion costs by $184
and $294, respectively (p < 0.0001). Being male, discharged to
home, and the use of topical sealants, were associated with lower
total transfusion costs. CONCLUSIONS: This study demon-
strates that the anatomical location, surgical approach, physician
specialty, and hospital characteristics are all associated with
blood transfusion costs. Newer technologies/medications may
reduce blood transfusion use/costs, and this potential for reduc-
tion may be even greater in certain subgroups.
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OBJECTIVE: To analyze blood transfusion patterns and associ-
ated costs in hip/knee replacement and revision surgeries in the
US inpatient setting. METHODS: This study used Premier’s US
Inpatient Comparative Database, containing approximately 5
million discharges annually, from over 500 hospitals. A total of
12,211 inpatient discharges with a primary procedure for hip
(ICD-9 codes 81.51, 81.53; US projected total: 274,542 proce-
dures) and 17,805 for knee arthroplasty (ICD-9 codes 81.54,
81.55; US projected total: 494,629 procedures) between July
2003 and June 2004 were evaluated. Blood management pat-
terns were examined pre- and post-surgery. The association
between surgery subtypes and transfusion costs were examined
using multivariate regression after controlling for various
patient-(age, race, gender, severity), hospital-(location, teaching
status, bedsize, region), and clinical-factors, inpatient mortality,
payer type (Medicare, Medicaid, commercial/managed care), and
physician specialty. RESULTS: Average (maximum) blood trans-
fusion costs of $448 ($11,838), $720 ($27,957), $321
($17,328), and $427 ($5182) were incurred for total hip replace-
ment, hip revision, knee replacement, and knee revision, respec-
tively. Multivariate analyses showed that hip and knee revision
costs were $272 and $66 higher than hip replacement, respec-
tively (p < 0.0001). Being operated on by an orthopedic surgeon
was associated with slightly lower total transfusion costs (p <
0.0001). Blood transfusion costs increased with increasing sever-
ity ($1049; p < 0.001), comparing most severe to mild. Use of
hypotensive anesthesia and topical sealants were associated with
a $131 and $101 reduction, respectively, whereas the use of ery-
thropoetic agents was associated with a $210 increase in total
transfusion costs (p < 0.0001). Blood transfusion costs increased
